CRYOLIFE, INC. (NYSE:CRY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Mr. James S. Benson, a director of CryoLife, Inc. (“the Company”) since 2005, notified the Company on March 14, 2017, of his decision not to stand for re-election as a director at the Company’s 2017 Annual Meeting of Shareholders. Mr. Benson’s decision not to stand for re-election was not due to any disagreement with management on any matter relating to the Company’s operations, policies, or practices.
About CRYOLIFE, INC. (NYSE:CRY)
CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company’s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces. CRYOLIFE, INC. (NYSE:CRY) Recent Trading Information
CRYOLIFE, INC. (NYSE:CRY) closed its last trading session up +0.25 at 16.60 with 148,560 shares trading hands.
